- Postdoctoral Fellow in Cancer Biology & Therapeutics, National Cancer Institute, Bethesda, MD
- Ph.D. in Pharmaceutical Sciences, University of Georgia, Athens, GA
- B.S. in Pharmacy, Shanghai Medical University (now Fudan University), China
- Associate Professor of Pharmaceutics and Drug Delivery
- Research Associate Professor in the Research Institute of Pharmaceutical Sciences
The primary research interest in Dr. Tan’s laboratory focuses on the synthesis and evaluation of novel long-circulating nanocarriers for the delivery of microRNAs and small-molecule anticancer drugs. By combining approaches in pharmaceutical sciences and cancer biology, we aim to construct highly robust nano-sized drug delivery systems with broad applicability to improve the efficacy of anticancer agents.
Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia (ATL). Cancer Res 62, 1083−6, 2002.
Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, Van Meir EG. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65, 605−12, 2005.
Mun J, Jabbar AA, Devi NS, Yin S, Wang Y, Tan C, Culver D, Snyder JP, Van Meir EG, Goodman MM. Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroaryl- sulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem 55, 6738−50, 2012.
Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One 8, e58619, 2013.
Wang Y, Fan W, Dai X, Katragadda U, Mckinley D, Teng Q, Tan C. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharmaceutics 11, 1140−50, 2014.
Fan W, Wang Y, Dai X, Shi L, Mckinley D, Tan C. Reduction-responsive crosslinked micellar nanoassemblies for tumor-targeted drug delivery. Pharm Res 32, 1325−40, 2015.
Dai X, Jiang Y, Tan C. Let-7 sensitizes KRAS mutant tumor cells to chemotherapy. PLoS One 10, e0126653, 2015.
Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Del Rev 81, 184−97, 2015.
Dai X, Fan W, Wang Y, Huang L, Jiang Y, Shi L, Mckinley D, Tan W, Tan C. Combined delivery of let-7b microRNA and paclitaxel via biodegradable nanoassemblies for the treatment of KRAS mutant cancer. Mol Pharmaceutics 13, 520−33, 2016.
Dai X, Kaluz S, Jiang Y, Shi L, Mckinley D, Wang Y, Wang B, Van Meir EG, Tan C. A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. Oncotarget 8, 99245−60, 2017.
POSTDOCTORAL POSITION AVAILABLE
Highly motivated and enthusiastic candidates are invited to lead projects devising novel drug delivery systems for cancer therapy. Applicants must have an MD or PhD degree in pharmaceutics, pharmacology, bioengineering, biology, chemistry or a related field. Expertise in animal studies and ability to perform and prioritize multiple simultaneous tasks are essential. Applicants should have experience in handling mice, HPLC analysis, cell culture, molecular/cellular biology techniques, cancer biology, and/or polymer chemistry. The position is available immediately with the possibility for annual contract renewal, please see the detailed information at https://jobs.olemiss.edu/postings/11860.